Your email has been successfully added to our mailing list.

×
0 0 0.263157894736842 0.34421052631579 0.593684210526316 0.595789473684211 0.504126315789474 0.378947368421053
Stock impact report

Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate

CONTRAVIR PHARMACEUTICALS INC (CTRV) 
US:NASDAQ Investor Relations: ir.contravir.com/investor-relations
Company Research Source: GlobeNewswire
EDISON, N.J., June 17, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced findings from its first study with human precision cut liver slice cultures. Liver disease was simulated in this unique experimental model by application of the potent, profibrotic molecules, TGFß and PDGF. Co-administration of ContraVir’s clinical phase drug candidate, CRV431, was found to be 100% effective at preventing fibrosis induction beyond baseline levels. CRV431 at clinically relevant concentrations also partially or completely blocked several genetic and protein biomarkers of inflammation (e.g. IL-6, MCP-1) and fibrosis (e.g. collagen, fibronectin, hyaluronic acid, TIMP-1). In this experiment, CRV431 was more effective at preventing fibrosis than elafibranor, a dual PPAR a/d Show less Read more
Impact Snapshot
Event Time:
CTRV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CTRV alerts
Opt-in for
CTRV alerts

from News Quantified
Opt-in for
CTRV alerts

from News Quantified